On April 11, 2023 MaaT Pharma (EURONEXT: MAAT – the "Company"), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, reported that promising clinical data for its drug candidates, MaaT013 and MaaT033 will be reported in two oral presentations by Pr. Florent Malard, Associate Professor of Hematology at the Saint-Antoine Hospital and Sorbonne University during the 49th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2023) to be held as an hybrid event in Paris, France, from April 23 – 26, 2023 (Press release, MaaT Pharma, APR 11, 2023, View Source [SID1234629949]). The EBMT Annual Meeting is a leading event in Europe that focuses on cutting-edge scientific content related to transplantation and cellular therapy. The oral presentations will include data that were previously presented at the American Society of Hematology (ASH) (Free ASH Whitepaper) conference in December 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Key clinical findings with MaaT013 as compassionate use in France (Early Access Program or "EAP") in 81 patients

Clinical results showed a GI-Overall Response Rate (ORR) of 56% including 30 complete responses (37%), 11 very good partial responses (14%) and 4 partial responses (5%) in GI-aGvHD patients 28 days after treatment initiation; 12-month overall survival was 59% in patients responding to MaaT013 treatment.
A 65% ORR was observed in 31 patients treated with MaaT013 as 3rd-line therapy after failure to 2nd-line ruxolitinib treatment; 12-month overall survival in this group responding to MaaT013 treatment was 74%; similar patient population is being treated in MaaT Pharma’s ongoing pivotal Phase 3 in Europe.
Oral Presentation details for MaaT013:

Title: Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-versus Host Disease: Results from the Early Access Program in France
Abstract number: OS05-08
Session Name: Oral Session 5 | GVHD (Clinical)
Date/Time: Wednesday, April 26, 2023 11:33 am – 11:42 am CET
Location: Amphithéâtre Bleu

Key clinical findings with MaaT033 in Phase 1b study CIMON

MaaT033 was shown to be safe and tolerable in 21 patients. 4 severe adverse events were reported in 4 patients, only one was considered as possibly related to the treatment by the investigator.
Treatment with MaaT033 induced increased microbiota richness as well as strong and persistent engraftment in cohorts 3 and 4 of the dose escalation study, which consisted of taking 3 capsules of the drug candidate per day.
Engraftment following MaaT033 treatment correlated with increased anti-inflammatory marker levels and reduced inflammatory marker levels in patients.
MaaT Pharma is preparing a randomized, double-blind, placebo-controlled pivotal Phase 2b clinical trial for MaaT033; trial start is expected in Q2 2023 as previously announced.
Oral Presentation details for MaaT033:

Title: Restoration of Gut Microbiota Diversity with Oral Pooled Fecal Microbiotherapy in Acute Myeloid Leukemia Patients after Intensive Chemotherapy: the Phase 1b CIMON trial
Abstract number: OS06-08
Session Name: Oral Session 6 | Acute Leukemia (II)
Date/Time: Wednesday, April 26, 2023 10:39 am – 10:48 am CET
Location: Maillot

Participants are also invited to meet with MaaT Pharma’s clinical team at booth #48. All EBMT sessions that take place onsite will be live-streamed through the congress platform and will be available on-demand after they are aired live. Link to register: View Source